Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.55 |
| ▸ | JAK2 | O60674 | 12/20 | 0.55 |
| ▸ | JAK1 | P23458 | 11/20 | 0.55 |
| ▸ | TYK2 | P29597 | 4/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22544617 | 0.93 | MAP4K1 (0.49) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL22097675 | 0.89 | JAK3 (0.56) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL31557671 | 0.89 | JAK3 (0.56) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL29754339 | 0.88 | FLT4 (0.51) | JAK3 | |
| SCHEMBL22545899 | 0.88 | FLT4 (0.51) | JAK3 | |
| SCHEMBL22544566 | 0.87 | JAK3 (0.51) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL27059237 | 0.87 | JAK3 (0.55) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL22544819 | 0.86 | LRRK2 (0.52) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL29754172 | 0.86 | LRRK2 (0.52) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL30891573 | 0.84 | JAK1 (0.56) | JAK3JAK2JAK1TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| WO-2020207414-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020206588-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.